When Forward Ventures general partner Ivor Royston was first presented with new technology from The Scripps Research Institute for generating libraries of pharmacological compounds, the first question he asked was, why start another combinatorial chemistry company?

Royston came up with two answers: the Scripps technology had novel features that make it more user-friendly than competing technologies; and the market for combinatorial chemistry is big enough to accommodate several companies.